共 50 条
RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target
被引:65
|作者:
Wang, Yanyan
[1
]
Anirudhan, Varada
[2
]
Du, Ruikun
[1
,3
,4
]
Cui, Qinghua
[1
,3
,4
]
Rong, Lijun
[2
]
机构:
[1] Shandong Univ Tradit Chinese Med, Coll Pharm, Jinan 250355, Shandong, Peoples R China
[2] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA
[3] Shandong Prov Collaborat Innovat Ctr Antiviral Tr, Jinan, Peoples R China
[4] Shandong Univ Tradit Chinese Med, Qingdao Acad Chinese Med Sci, Qingdao, Peoples R China
关键词:
coronavirus;
COVID-19;
drug target;
RdRp;
SARS-CoV-2;
NUCLEOSIDE/NUCLEOTIDE ANALOG INHIBITORS;
RESPIRATORY SYNDROME CORONAVIRUS;
DE-NOVO INITIATION;
SARS-CORONAVIRUS;
INFLUENZA-A;
EBOLA-VIRUS;
ZIKA VIRUS;
IN-VITRO;
NUCLEOSIDE ANALOGS;
INTERFERON-BETA;
D O I:
10.1002/jmv.26264
中图分类号:
Q93 [微生物学];
学科分类号:
071005 ;
100705 ;
摘要:
The global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), named coronavirus disease 2019, has infected more than 8.9 million people worldwide. This calls for urgent effective therapeutic measures. RNA-dependent RNA polymerase (RdRp) activity in viral transcription and replication has been recognized as an attractive target to design novel antiviral strategies. Although SARS-CoV-2 shares less genetic similarity with SARS-CoV (similar to 79%) and Middle East respiratory syndrome coronavirus (similar to 50%), the respective RdRps of the three coronaviruses are highly conserved, suggesting that RdRp is a good broad-spectrum antiviral target for coronaviruses. In this review, we discuss the antiviral potential of RdRp inhibitors (mainly nucleoside analogs) with an aim to provide a comprehensive account of drug discovery on SARS-CoV-2.
引用
收藏
页码:300 / 310
页数:11
相关论文